ScripBeijing Biostar Pharmaceuticals, a Chinese chemotherapy specialist, intends to ride a planned Hong Kong initial public offering to support a global comparative Phase II/III trial for its lead drug in
ScripAllarity Therapeutics A/S ’s drug response predictor (DRP) technology when used with the chemotherapy Ixempra has shown early promise in a Phase II metastatic breast cancer trial, thrusting the compan
In VivoA beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic
Pink SheetA beneficial effect of sponsorship by the largest companies in the pharma industry can be seen in the fates of novel agent applications that faced US FDA approval decisions in recent years: the applic